Since its establishment, Keymed Biosciences has been focusing on the in-house R & D of innovative biological therapies, building a diversified pipeline for autoimmunity and oncology, and advancing a number of clinical studies on innovative products.
- CM310 -
· Innovative drug for atopic dermatitis, asthma, chronic sinusitis with polyps, chronic obstructive pulmonary disease, etc.
· The first domestic IL-4Rα antibody approved by NMPA for clinical trials.
- CMG901 -
· The first Claudin 18.2 antibody-drug conjugate approved for clinical trials in China and the United States.
Integrate advanced high-throughput screening platforms to rapidly discover therapeutic antibody candidates using hybridoma, in vitro display, and single B cell screening techniques.
Realize the construction and screening of stable high-expressing cell strains and the integration of cell culture, purification, preparation process development, and transfer of production technology.
Quality research and control platform featuring antibody drug characterization, purity and impurity analysis, and bioactivity analysis.
Commercial manufacturing bases complying with GMP standards in China, the United States, and the European Union are expected to start operating in 2022, providing an additional capacity of 16,000 L.
Keymed Biosciences adheres to the concept of "people-oriented and co-development with employees", advocates diversification and inclusiveness, and attaches great importance to the introduction and training of talents to continuously establish a stronger and more united Keymed Biosciences family.